register

News & Trends - Pharmaceuticals

AbbVie New Zealand welcomes new leadership as global moves unfold

Health Industry Hub | February 9, 2024 |

Pharma News: AbbVie has announced the appointment of Elhussein Abdellatif as the new Country Head for New Zealand. Reporting directly to Nathalie McNeil, Vice President and General Manager of AbbVie Australia & New Zealand, Hussein brings a wealth of experience and expertise to his new role.

Hussein takes over from Kylie Pennington, who has been at the helm of AbbVie New Zealand since May 2022. Kylie has been appointed General Manager for Skyrizi Dermatology, International Marketing & Commercial Operations (IMCO), reporting to Felipe Palacios, VP, Immunology, IMCO.

With a degree in Pharmaceutical Science from Ain Shams University in Egypt and over 18 years of industry experience spanning various roles and therapeutic areas, including Immunology, Oncology, Neuroscience, and HCV, Hussein is well-equipped to lead the New Zealand team.

Having been with AbbVie for nine years, Hussein initially joined AbbVie Saudi Arabia in 2015, progressing through the ranks. His most recent role was as the Oncology Commercial Director, Intercontinental, based in the US. Prior to joining AbbVie, Hussein gained valuable experience at MSD, Lundbeck, and Novartis, where he held roles in sales and marketing.

Ms McNeil expressed enthusiasm about Hussein’s appointment, stating, “We are excited to have Hussein join and lead the New Zealand team to build on the strong foundations already in place. His promotion, along with Kylie’s promotion to a global role, demonstrates AbbVie’s commitment to developing key talent and creating compelling career opportunities. We also thank Kylie for her leadership over the past two years in the Country Head role.”

Hussein officially assumed his new role last month and is currently in the process of relocating from Chicago to New Zealand with his family. In a parallel move, Kylie Pennington and her family are also relocating, making the journey from Auckland to Chicago.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.